This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The initial consideration for the transaction is US$ 12 million
The endorsement follows overwhelming support for the share swap preceding the merger,
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Subscribe To Our Newsletter & Stay Updated
